MIR1915HG

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, MIR1915HG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR1915HG data layer compared with 29 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher MIR1915HG Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR1915HG expression acts as an unfavorable survival marker.

LIHC are the cancer types where MIR1915HG Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
LIHCDFSMedianAll0.0910.543.0129view →
Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration